Latest / Community Health Media
Dr. Komal Jhaveri, Dr. Shanu Modi, & Dr. Sarah Tolaney - Early Stage HER2+ Breast Cancer: DB11 & DB05
The treatment landscape for early-stage HER2-positive breast cancer has shifted.
Dr. Komal Jhaveri, Dr. Sarah Tolaney, and Dr. Shanu Modi discuss the landmark FDA approvals of trastuzumab deruxtecan (T-DXd) in the early-stage setting, and break down the practice-changing data from the DESTINY-Breast11 and DESTINY-Breast05 trials. They discuss what these results mean for clinical practice and patient care today.
The conversation explores:
How DESTINY-Breast11 is changing neoadjuvant treatment strategies
Which patients are most appropriate for T-DXd in early-stage HER2-positive disease…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.